The Vietnamese pharmaceutical industry is entering a highly strategic transitional phase, shifting aggressively from traditional competitive parameters — such as capital scale, plant capacity, and baseline generic drug portfolios — toward high-margin, sophisticated market segments. The structural evolution prioritizes high-tech medicines, biologics, bioequivalent therapies, and clinical solutions requiring intensive Research and Development (R&D) frameworks. This comprehensive overhaul of the industrial value chain establishes an urgent demand for a highly skilled workforce equipped with interdisciplinary capabilities and advanced technological literacy to operate the modern healthcare ecosystem.
The primary strategic milestones and human resource development frameworks defining the sector feature:
-
Coordinating Professional Training for the Digital Era: On the morning of May 21, 2026, Can Tho University of Medicine and Pharmacy, in partnership with Imexpharm Pharmaceutical Joint Stock Company, hosted a specialized scientific conference titled “Pharmacy Professional Competency in the Digital Age: Career Opportunities in Manufacturing, Quality, and Commercial Operations.” The summit served as a critical platform for medical experts, corporate executives, and students to analyze updated competence metrics, emphasizing that technology and human capital must advance in tandem to optimize public health outcomes.
-
Adaptation Criteria and Artificial Intelligence Literacy: Assoc. Prof. Dr. Do Chau Minh Vinh Tho, Vice Dean of the Faculty of Pharmacy at Can Tho University of Medicine and Pharmacy, noted that amidst continuous regulatory and technological iterations, the capacity for self-learning and rapid adaptation is the decisive factor for students. From a corporate operations perspective, Dr. Nguyen Vinh Luon, Human Resources Director at Imexpharm, emphasized that modern workplace demand has expanded to require robust data utilization skills and AI compatibility. He urged the upcoming generation of pharmacists to interact with AI responsibly and effectively, utilizing it as a powerful virtual assistant rather than blindly over-relying on the technology.
-
Technology-Driven R&D Transition via International Alliances: To successfully penetrate high-value pharmaceutical segments, Imexpharm is actively scaling up its baseline R&D capacities through strategic international partnerships. Most notable is its commercial alliance with Livzon, a top-25 pharmaceutical institution in China possessing a portfolio with U.S. FDA-cleared products. This cross-border collaboration is projected to act as a strategic lever, accelerating the domestic industry’s transition from an “experience-driven” to a “technology-driven” R&D model while streamlining alignment with international standards.
-
National Alignment for Sustainable Healthcare Integration: This macro corporate vision of anchoring long-term expansion on high-quality human capital aligns with the core directives of Vietnam’s National Strategy for Public Health Protection, Care, and Promotion to 2030, with a Vision to 2045 (promulgated under Prime Minister Decision No. 89/QD-TTg dated January 23, 2024). The statutory decree formally designates healthcare human resources as the fundamental cornerstone for the sustainable development of the entire sector.
Imexpharm’s executive leadership reiterated that while manufacturing technologies can be purchased and specialized facilities constructed, a highly qualified talent pool represents an intrinsic asset that cannot be established overnight. Cultivating advanced professional competencies within university lecture halls is deemed an essential prerequisite to securing the long-term macroeconomic and clinical competitiveness of Vietnam’s pharmaceutical sector on the global stage.